BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on flupirtine: recall and revocation of marketing authorisation

2018.06.04

Active substance: flupirtine

Following the European benefit-risk assessment, marketing authorisations of medicinal products containing the active substance flupirtine are revoked on an EU-wide level due to the risk of liver damage.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 36KB, File is accessible